Zobrazeno 1 - 10
of 49
pro vyhledávání: '"Holly Tovey"'
Autor:
Eugene F. Schuster, Elena Lopez-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Maggie Chon U. Cheang, Holly Tovey, Manuel Salto-Tellez, Perry Maxwell, John Robertson, Ian Smith, Judith M. Bliss, Mitch Dowsett
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Aromatase inhibitors (AIs) reduce recurrences and mortality in postmenopausal patients with oestrogen receptor positive (ER+) breast cancer (BC), but >20% of patients will eventually relapse. Given the limited understanding of intrinsic resi
Externí odkaz:
https://doaj.org/article/ac7abf0f898945ac9498001b487931f6
Autor:
Judith M. Bliss, Holly Tovey, Abigail Evans, Chris Holcombe, Kieran Horgan, Elizabeth Mallon, Raghavan Vidya, Anthony Skene, Andrew Dodson, Margaret Hills, Simone Detre, Lila Zabaglo, Jane Banerji, Lucy Kilburn, James P. Morden, John F. R. Robertson, Ian Smith, Mitch Dowsett, the POETIC Trialists
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-16 (2023)
Abstract Purpose Ki67 assessed at diagnosis (Ki67baseline) is an important prognostic factor in primary oestrogen receptor-positive (ER +) breast cancer. Proportional change in Ki67 after 2 weeks (∆Ki672week) is associated with clinical benefit fro
Externí odkaz:
https://doaj.org/article/46abcee1eee44a268049c2e73c029025
Autor:
Elena Lopez-Knowles, Simone Detre, Margaret Hills, Eugene F. Schuster, Maggie C. U. Cheang, Holly Tovey, Lucy S. Kilburn, Judith M. Bliss, John Robertson, Elizabeth Mallon, Anthony Skene, Abigail Evans, Ian Smith, Mitch Dowsett
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-10 (2022)
Abstract Background In clinical practice, oestrogen receptor (ER) analysis is almost entirely by immunohistochemistry (IHC). ASCO/CAP recommends cut-offs of
Externí odkaz:
https://doaj.org/article/b69c05c893f24935a330283cbc7187d8
Autor:
Anna Wilkins, Barry Gusterson, Holly Tovey, Clare Griffin, Christine Stuttle, Frances Daley, Catherine M. Corbishley, David Dearnaley, Emma Hall, Navita Somaiah
Publikováno v:
EBioMedicine, Vol 88, Iss , Pp 104436- (2023)
Summary: Background: Protein markers of cellular proliferation, hypoxia, apoptosis, cell cycle checkpoints, growth factor signalling and inflammation in localised prostate tumours have previously shown prognostic ability. A translational substudy wit
Externí odkaz:
https://doaj.org/article/a5b636b3bc8543eaa61edfe616f51293
Autor:
Neha Chopra, Holly Tovey, Alex Pearson, Ros Cutts, Christy Toms, Paula Proszek, Michael Hubank, Mitch Dowsett, Andrew Dodson, Frances Daley, Divya Kriplani, Heidi Gevensleben, Helen Ruth Davies, Andrea Degasperi, Rebecca Roylance, Stephen Chan, Andrew Tutt, Anthony Skene, Abigail Evans, Judith M. Bliss, Serena Nik-Zainal, Nicholas C. Turner
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Defects in homologous recombination (HR) are found in some triple negative breast cancers, suggesting they may be sensitive to PARP inhibitors. In this phase II clinical trial of the PARP inhibitor rucaparib, changes in Ki67 levels did not correlate
Externí odkaz:
https://doaj.org/article/16335d8252804f3a9e5594503bbf84fa
Autor:
Susana Banerjee, Holly Tovey, Rebecca Bowen, Elizabeth Folkerd, Lucy Kilburn, Jennifer McLachlan, Marcia Hall, Nina Tunariu, Ayoma Attygalle, Joao Paulo Da Silveira Nogueira Lima, Sophie Perry, Peter Chatfield, Margaret Hills, Stan Kaye, Gert Attard, Mitch Dowsett, Judith M. Bliss
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: Recurrent epithelial ovarian cancer (EOC) remains difficult to treat, with an urgent need for more therapy options. Androgens bind to the androgen receptor (AR), commonly expressed in EOC. CYP17 inhibitor abiraterone irreversibly inhibits
Externí odkaz:
https://doaj.org/article/573e022757c443b698c2911c247d9712
Autor:
Eugene F. Schuster, Elena López-Knowles, Anastasia Alataki, Lila Zabaglo, Elizabeth Folkerd, David Evans, Kally Sidhu, Holly Tovey, Perry Maxwell, Nicholas Turner, Stephen Johnston, Manuel Salto-Tellez, Maggie Chon U Cheang, John Robertson, Ian Smith, Judith Bliss, Mitch Dowsett
Publikováno v:
Cancer Research. 83:PD10-07
Background: Aromatase inhibitors (AIs) are highly effective at reducing recurrences and mortality in postmenopausal patients with estrogen receptor positive breast cancer (ER+ BC). Poor anti-proliferative (Ki67) response or ER+ BCs to AIs after 2 wee
Autor:
Anastasia Alataki, Gene Schuster, Lila Zabaglo, Perry Maxwell, Elena López-Knowles, Elizabeth Folkerd, David Evans, Kally Sidhu, Holly Tovey, Nicholas Turner, Stephen Johnston, Maggie Chon U Cheang, John Robertson, Manuel Salto-Tellez, Ian Smith, Judith Bliss, Mitch Dowsett
Publikováno v:
Cancer Research. 83:PD10-08
Background: Aromatase inhibitors (AIs) are one of the main treatment strategies for the clinical management of estrogen receptor-positive (ER+) breast cancer (BC). Despite prolonged time to recurrence and initial clinical responses, >20% of patients
Autor:
Maggie C.U. Cheang, Mitch Dowsett, Ian E. Smith, John F.R. Robertson, Judith M. Bliss, Holly Tovey, Elena López-Knowles, Mariana F. Leal, Eugene F. Schuster, Joel Parker, Gabriele Morani, Milana A. Bergamino
Purpose:Aromatase inhibitor (AI) treatment is the standard of care for postmenopausal women with primary estrogen receptor–positive breast cancer. The impact of duration of neoadjuvant endocrine therapy (NET) on molecular characteristics is still u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3859c199a85fa9de6d1a8dff4f5a175e
https://doi.org/10.1158/1078-0432.c.6531071
https://doi.org/10.1158/1078-0432.c.6531071
Autor:
Maggie C.U. Cheang, Mitch Dowsett, Ian E. Smith, John F.R. Robertson, Judith M. Bliss, Holly Tovey, Elena López-Knowles, Mariana F. Leal, Eugene F. Schuster, Joel Parker, Gabriele Morani, Milana A. Bergamino
Supplementary Data from Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29c81796eb9b16542f2ec7ff684d2b3c
https://doi.org/10.1158/1078-0432.22483103.v1
https://doi.org/10.1158/1078-0432.22483103.v1